Filing Details

Accession Number:
0001387131-19-007016
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-09-18 16:40:39
Reporting Period:
2019-09-17
Accepted Time:
2019-09-18 16:40:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1692830 Satsuma Pharmaceuticals Inc. STSA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
860866 David Bonderman C/O Tpg Global, Llc,
301 Commerce Street, Suite 3300
Fort Worth TX 76102
No No Yes No
1099776 G James Coulter C/O Tpg Global, Llc,
301 Commerce Street, Suite 3300
Fort Worth TX 76102
No No Yes No
1495741 Tpg Group Holdings (Sbs) Advisors, Inc. C/O Tpg Global, Llc
301 Commerce Street, Suite 3300
Fort Worth TX 76102
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-09-17 1,785,939 $0.00 1,785,939 No 4 C Indirect See Explanation of Responses
Common Stock Acquisiton 2019-09-17 100,000 $15.00 1,885,939 No 4 P Indirect See Explanation of Responses
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Explanation of Responses
No 4 P Indirect See Explanation of Responses
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2019-09-17 1,004,205 $0.00 1,004,205 $0.00
Common Stock Series B Preferred Stock Disposition 2019-09-17 781,734 $0.00 781,734 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of TPG Biotechnologies GenPar V Advisors, LLC, which is the general partner of TPG Biotechnology GenPar V, L.P., which is the general partner of TPG Biotechnology Partners V, L.P. ("TPG Biotech V"), which directly holds 1,885,939 shares of Common Stock ("Common Stock") of Satsuma Pharmaceuticals, Inc. (the "Issuer").
  2. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer (the "Certificate of Incorporation"), on September 17, 2019, the (a) shares of Series A Preferred Stock of the Issuer held by TPG Biotech V automatically converted into 1,004,205 shares of Common Stock and (b) shares of Series B Preferred Stock of the Issuer (together with the Series A Preferred Stock, the "Preferred Stock") held by TPG Biotech V automatically converted into 781,734 shares of Common Stock. Pursuant to the Certificate of Incorporation, the Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Preferred Stock.
  3. On September 17, 2019, in connection with the Issuer's initial public offering, TPG Biotech V acquired 100,000 shares of Common Stock at a price of $15.00 per share.
  4. Because of the relationship between the Reporting Persons and TPG Biotech V, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of TPG Biotech V. Each of TPG Biotech V and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of TPG Biotech V's or such Reporting Person's pecuniary interest therein, if any.
  5. Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.